---
title: "Investigational New Drug "
slug: "/en/learn/investigational-new-drug--102165"
id: "102165"
hide_table_of_contents: true
---

import { ArticleMeta } from "@site/src/components/article-meta";
import { AIContent } from "@site/src/components/ai-content";

# Investigational New Drug 

<ArticleMeta id={102165} updatedAt={'2024-09-12 17:39:36'} />
<div className='border-solid border-b border-t-0 my-4 border-[var(--ifm-color-gray-300)]' />

<p>An Investigational New Drug (IND) is a drug that has not yet received market approval and is being evaluated for safety and efficacy in humans. INDs are typically developed by pharmaceutical companies or research institutions and must receive approval from relevant regulatory authorities (such as the U.S. Food and Drug Administration, FDA) before proceeding with clinical trials.</p><p>Key characteristics include:</p><p>Development Stage: INDs are in the preclinical or clinical trial stages of drug development and have not yet received market approval.<br/>Clinical Trials: INDs are used to conduct human clinical trials to assess their therapeutic effects, safety, and dosage range.<br/>Regulatory Approval: An IND application must be submitted and approved by regulatory authorities before clinical trials can begin.<br/>Data Collection: Data collected during clinical trials are used to support future New Drug Application (NDA) submissions.<br/>Example of Investigational New Drug application:<br/>Suppose a pharmaceutical company develops a new anti-cancer drug that has shown promising results in animal studies. The company submits an IND application to the FDA, including the drug's chemical composition, manufacturing process, animal study data, and planned clinical trial protocol. After FDA review and approval, the company begins human clinical trials to evaluate the drug's safety and efficacy.</p>

<AIContent content={`<p><strong>Definition:</strong><br/>An Investigational New Drug (IND) is a drug that has not yet received market approval and is used to evaluate its safety and efficacy in humans. INDs are typically developed by pharmaceutical companies or research institutions and must receive approval from relevant regulatory agencies (such as the U.S. Food and Drug Administration, FDA) before clinical trials can be conducted.</p><p><strong>Origin:</strong><br/>The concept of Investigational New Drugs originated in the mid-20th century as drug development and regulatory systems became more sophisticated. In the United States, the FDA's 1962 Drug Amendments Act mandated that new drugs must undergo rigorous clinical trials and approval processes before entering the market. This system ensures the safety and efficacy of new drugs before they are marketed.</p><p><strong>Categories and Characteristics:</strong><br/>1. <strong>Development Stage:</strong> INDs are in the preclinical or clinical trial stages of drug development and have not yet received market approval.<br/>2. <strong>Clinical Trials:</strong> INDs are used in human clinical trials to evaluate their therapeutic effects, safety, and dosage range.<br/>3. <strong>Regulatory Approval:</strong> Before conducting clinical trials, an IND application must be submitted and approved by regulatory agencies.<br/>4. <strong>Data Collection:</strong> Data collected during clinical trials are used to support future New Drug Applications (NDA).</p><p><strong>Specific Cases:</strong><br/>1. <strong>Anti-cancer Drug Development:</strong> Suppose a pharmaceutical company develops a new anti-cancer drug that shows promising results in animal studies. The company submits an IND application to the FDA, including the drug's chemical composition, manufacturing process, animal study data, and proposed clinical trial plan. After FDA approval, the company begins human clinical trials to evaluate the drug's safety and efficacy.<br/>2. <strong>Vaccine Development:</strong> During the COVID-19 pandemic, many pharmaceutical companies and research institutions rapidly developed multiple vaccine candidates and submitted IND applications. Through expedited clinical trials, these vaccines received emergency use authorizations in a short period, helping to control the spread of the virus.</p><p><strong>Common Questions:</strong><br/>1. <strong>How long does it take to approve an IND application?</strong><br/>Typically, the FDA responds within 30 days of receiving an IND application. If no major issues are found, the application will be approved, and clinical trials can begin.<br/>2. <strong>What should be done if an IND application is rejected?</strong><br/>If the application is rejected, the applicant can revise and supplement the application based on FDA feedback and resubmit it.</p>`} id={102165} />
